A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DS / differentiation syndrome

[Related PubMed/MEDLINE]
Total Number of Papers: 37
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DS  (>> Co-occurring Abbreviation)
Long Form:   differentiation syndrome
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Predictors of early hemorrhage in acute promyelocytic leukemia. APL, LDH, WBC
2019 Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-kappaB activation. APL, IL-1beta, TNF-alpha
2018 Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. AML, IDH-DS, IDH2, R/R
2018 Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment. APL, ATRA, CI, CR, OR, WBC
2017 Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide. APL, ATO, ECOG, ED
2017 Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE). APL, ED, UAE
2017 HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells. APL, ATO, ATRA, HMGB1
2017 In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome. APL, ATRA, DIC, ICAM-1, RA, rTM, TNF-alpha
2017 [Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia]. APL, DFS, OS
10  2016 Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. AML, IDH
11  2016 Integrating microRNA and mRNA expression profiles of acute promyelocytic leukemia cells to explore the occurrence mechanisms of differentiation syndrome. APL, KEGG, miRNA
12  2016 Severe stomatitis and ileocecal perforation developed after all-trans retinoic acid monotherapy in an HLA-B51-positive patient with acute promyelocytic leukemia. APL, ATRA
13  2016 [Establishment and assessment of a nomogram for predicting the differentiation syndrome of acute promyelocytic leukemia]. APL, BMI, C-index
14  2014 Celastrol inhibits lung infiltration in differential syndrome animal models by reducing TNF-alpha and ICAM-1 levels while preserving differentiation in ATRA-induced acute promyelocytic leukemia cells. APL, ATRA
15  2014 Congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia. APL, CHF, EF
16  2014 How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. ---
17  2014 Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. ---
18  2014 Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome. ---
19  2014 Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. APL, ATRA, ED, WBC
20  2013 All-trans retinoic Acid differentiation syndrome chorioretinopathy: a case of multifocal serous neurosensory detachments in a patient with acute promyelocytic leukemia treated with all-trans retinoic Acid. ATRA
21  2013 Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. ATRA
22  2012 Differentiation syndrome in patients with acute promyelocytic leukemia. APL, ATO, ATRA
23  2012 Role of lipoxin A4 in the cell-to-cell interaction between all-trans retinoic acid-treated acute promyelocytic leukemic cells and alveolar macrophages. APL, ATRA, ATRA-NR8383, CM
24  2011 Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. APL, ATRA, DFS, OS
25  2011 ATRA and anthracycline-based chemotherapy in the treatment of childhood acute promyelocytic leukemia (APL): A 10-year experience in Tunisia. APL
26  2011 Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment. APL, ATO, ATRA
27  2011 Recurrent differentiation syndrome or septic shock? Unresolved dilemma in a patient with acute promyelocytic leukemia. APL, ATRA
28  2011 The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. APL, ATO, ATRA
29  2011 Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center Study. ---
30  2010 Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. APL
31  2010 High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. ---
32  2010 Interaction of SDF-1alpha and CXCR4 plays an important role in pulmonary cellular infiltration in differentiation syndrome. APL, ATRA, SDF-1alpha
33  2010 Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience. APL, ATRA, CR
34  2009 Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. APL, ATRA
35  2009 Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. APL, ATRA, PETHEMA
36  2007 Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. APL, ATRA, PB
37  2007 The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. APL, ATRA